• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,000
83
62
59
47

COUNTRY

57
19
10
7
5

CATEGORIES

  • 85
  • 124
  • 66
  • 65
  • 37
  • 36
  • 12
  • 12
  • 12
  • 18

PRICE

139
614
1,000
2,706

PUBLISHED

9
149
647
2,706

PRODUCT TYPE

2,599
87
12
7
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013

Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

September 2013
FROM

Nonhematologic Malignancy - Pipeline Review, H2 2013

Nonhematologic Malignancy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Nonhematologic Malignancy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

September 2013
FROM

Renal Cell Carcinoma - Pipeline Review, H2 2013

Renal Cell Carcinoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Renal Cell Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

September 2013
FROM

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013', provides an overview of the indication’s...

September 2013
FROM

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2013

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review,...

September 2013
FROM

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013', provides an overview...

September 2013
FROM

Metastatic Cancer - Pipeline Review, H2 2013

Metastatic Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Metastatic Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

September 2013
FROM

Metastatic Melanoma - Pipeline Review, H2 2013

Global Markets Direct's, 'Metastatic Melanoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development...

September 2013
FROM

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

September 2013
FROM

Oncology Drug Funding 2013

A Comprehensive Intelligence Report on Oncology Drug Funding 2013 is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid...

September 2013

Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

The report (ToC) provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC)...

September 2013
FROM

Non-Small Cell Lung Cancer Thought Leader Panel #36 2013-09

Thought Leader Panel #36, published September 2013, shares key insights gleaned from our Panel of experts in non-small cell lung cancer during interviews conducted since ASCO 2013 This report focuses...

September 2013

Global Cancer Vaccines Pipeline Analysis

Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments With the approval of the expensive prostate cancer vaccine, Provenge...

September 2013
FROM

Bone Metastasis - Pipeline Review, H2 2013

Bone Metastasis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Bone Metastasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

August 2013
FROM

Melanoma - Pipeline Review, H2 2013

Melanoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Melanoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

August 2013
FROM

Lymphoma - Pipeline Review, H2 2013

Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

August 2013
FROM

Gastrointestinal Tract Cancer - Pipeline Review, H2 2013

Gastrointestinal Tract Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Gastrointestinal Tract Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

August 2013
FROM

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013', provides an overview...

August 2013
FROM

Oral Mucositis - Pipeline Review, H2 2013

Oral Mucositis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Oral Mucositis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

August 2013
FROM

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2013

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder...

August 2013
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)